Pfizer's biosimilar equivalent to Rituxan in Phase III for follicular lymphoma

Pfizer Inc. (NYSE:PFE) reported top-line data from the Phase III REFLECTIONS B3281006 trial showing that PF-05280586, a biosimilar of rituximab, as first-line treatment of CD20-positive, low tumor burden follicular lymphoma met the primary endpoint of equivalence to Rituxan/MabThera rituximab in overall response rate (ORR). The company declined to provide details on its plans for regulatory submissions. Rituximab is a chimeric mAb against CD20 antigen from Roche (SIX:ROG; OTCQX:RHHBY)...